APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Myeloid Leukaemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Acute Myeloid Leukaemia Therapeutics Industry Growth and Trends Forecast to 2032

Report ID 17405230014 March 2026104 pages

Choose your research edition.

Industry ResearchAcute Myeloid Leukaemia Therapeutics Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Myeloid Leukaemia Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Acute Myeloid Leukaemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Myeloid Leukaemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Myeloid Leukaemia Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

According to APO Research, the global Acute Myeloid Leukaemia Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Myeloid Leukaemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Acute Myeloid Leukaemia Therapeutics market include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson and Gilead Sciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Acute Myeloid Leukaemia Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Acute Myeloid Leukaemia Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Acute Myeloid Leukaemia Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Acute Myeloid Leukaemia Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Acute Myeloid Leukaemia Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Acute Myeloid Leukaemia Therapeutics Market by Company

Pfizer Inc.

Novartis AG

Celgene Corporation

Astellas Pharma Inc.

Daiichi Sankyo Company, Limited

Jazz Pharmaceuticals

Boehringer Ingelheim International GmbH

Johnson & Johnson

Gilead Sciences, Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Sunesis Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Acute Myeloid Leukaemia Therapeutics Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hypomethylating Agents

Others

Acute Myeloid Leukaemia Therapeutics Segment by Application

Specialty Clinics

Hospital

Others

Acute Myeloid Leukaemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Myeloid Leukaemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Myeloid Leukaemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Myeloid Leukaemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Acute Myeloid Leukaemia Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Acute Myeloid Leukaemia Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region (2021-2026) Table 4. Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region (2027-2032) Table 6. Global Acute Myeloid Leukaemia Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Acute Myeloid Leukaemia Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Acute Myeloid Leukaemia Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Acute Myeloid Leukaemia Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Acute Myeloid Leukaemia Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Acute Myeloid Leukaemia Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Acute Myeloid Leukaemia Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Acute Myeloid Leukaemia Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Acute Myeloid Leukaemia Therapeutics Industry Trends Table 37. Acute Myeloid Leukaemia Therapeutics Industry Drivers Table 38. Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges Table 39. Acute Myeloid Leukaemia Therapeutics Industry Restraints Table 40. Global Acute Myeloid Leukaemia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Acute Myeloid Leukaemia Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Acute Myeloid Leukaemia Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Acute Myeloid Leukaemia Therapeutics Key Company Headquarters & Area Served Table 44. Global Acute Myeloid Leukaemia Therapeutics Company, Product Type & Application Table 45. Global Acute Myeloid Leukaemia Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Acute Myeloid Leukaemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Pfizer Inc. Company Information Table 49. Pfizer Inc. Business Overview Table 50. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 52. Pfizer Inc. Recent Development Table 53. Novartis AG Company Information Table 54. Novartis AG Business Overview Table 55. Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 57. Novartis AG Recent Development Table 58. Celgene Corporation Company Information Table 59. Celgene Corporation Business Overview Table 60. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 62. Celgene Corporation Recent Development Table 63. Astellas Pharma Inc. Company Information Table 64. Astellas Pharma Inc. Business Overview Table 65. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 67. Astellas Pharma Inc. Recent Development Table 68. Daiichi Sankyo Company, Limited Company Information Table 69. Daiichi Sankyo Company, Limited Business Overview Table 70. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 72. Daiichi Sankyo Company, Limited Recent Development Table 73. Jazz Pharmaceuticals Company Information Table 74. Jazz Pharmaceuticals Business Overview Table 75. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 77. Jazz Pharmaceuticals Recent Development Table 78. Boehringer Ingelheim International GmbH Company Information Table 79. Boehringer Ingelheim International GmbH Business Overview Table 80. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 82. Boehringer Ingelheim International GmbH Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Gilead Sciences, Inc. Company Information Table 89. Gilead Sciences, Inc. Business Overview Table 90. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 92. Gilead Sciences, Inc. Recent Development Table 93. Amgen Inc. Company Information Table 94. Amgen Inc. Business Overview Table 95. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 97. Amgen Inc. Recent Development Table 98. Takeda Pharmaceutical Company Limited Company Information Table 99. Takeda Pharmaceutical Company Limited Business Overview Table 100. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 102. Takeda Pharmaceutical Company Limited Recent Development Table 103. Sunesis Pharmaceuticals, Inc. Company Information Table 104. Sunesis Pharmaceuticals, Inc. Business Overview Table 105. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 107. Sunesis Pharmaceuticals, Inc. Recent Development Table 108. Agios Pharmaceuticals, Inc. Company Information Table 109. Agios Pharmaceuticals, Inc. Business Overview Table 110. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio Table 112. Agios Pharmaceuticals, Inc. Recent Development Table 113. North America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 115. North America Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2026) Table 116. North America Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. North America Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Country (2027-2032) Table 118. Europe Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 120. Europe Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2026) Table 121. Europe Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Europe Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2026) Table 126. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Country (2027-2032) Table 128. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Latin America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 130. Latin America Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2026) Table 131. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Latin America Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Country (2027-2032) Table 133. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 135. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2026) Table 136. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Share Forecast by Country (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Acute Myeloid Leukaemia Therapeutics Product Image Figure 3. Global Acute Myeloid Leukaemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Acute Myeloid Leukaemia Therapeutics Market Share by Region (2021-2032) Figure 7. North America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Chemotherapy Image Figure 13. Global Chemotherapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Targeted Therapy Image Figure 15. Global Targeted Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Immunotherapy Image Figure 17. Global Immunotherapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Hypomethylating Agents Image Figure 19. Global Hypomethylating Agents Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Acute Myeloid Leukaemia Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Acute Myeloid Leukaemia Therapeutics Market Share by Type 2025 VS 2032 Figure 24. North America Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2032) Figure 25. Europe Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2032) Figure 27. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Share by Type (2021-2032) Figure 29. Specialty Clinics Image Figure 30. Global Specialty Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Hospital Image Figure 32. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Others Image Figure 34. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Acute Myeloid Leukaemia Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Acute Myeloid Leukaemia Therapeutics Market Share by Application 2025 VS 2032 Figure 37. North America Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2032) Figure 38. Europe Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2032) Figure 40. Latin America Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Acute Myeloid Leukaemia Therapeutics Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Acute Myeloid Leukaemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Acute Myeloid Leukaemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2032) Figure 47. Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Acute Myeloid Leukaemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2032) Figure 50. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2032) Figure 53. Latin America Acute Myeloid Leukaemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Acute Myeloid Leukaemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2032) Figure 56. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hypomethylating Agents
  • Others
Applications
  • Specialty Clinics
  • Hospital
  • Others
Companies covered
  • Pfizer Inc.
  • Novartis AG
  • Celgene Corporation
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • Jazz Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Sunesis Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Acute Myeloid Leukaemia Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Acute Myeloid Leukaemia Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (2021-2032)
2 Acute Myeloid Leukaemia Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Chemotherapy
  3. 2.1.2 Targeted Therapy
  4. 2.1.3 Immunotherapy
  5. 2.1.4 Hypomethylating Agents
  6. 2.1.5 Others
  7. 2.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Type
  8. 2.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Acute Myeloid Leukaemia Therapeutics Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Acute Myeloid Leukaemia Therapeutics Market Size by Regions
  12. 2.3.1 North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Type (2021-2026)
3 Acute Myeloid Leukaemia Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Specialty Clinics
  3. 3.1.2 Hospital
  4. 3.1.3 Others
  5. 3.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Application
  6. 3.2.1 Global Acute Myeloid Leukaemia Therapeutics Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Acute Myeloid Leukaemia Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Acute Myeloid Leukaemia Therapeutics Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Acute Myeloid Leukaemia Therapeutics Market Size by Regions
  10. 3.3.1 North America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Acute Myeloid Leukaemia Therapeutics Industry Trends
  2. 4.2 Acute Myeloid Leukaemia Therapeutics Industry Drivers
  3. 4.3 Acute Myeloid Leukaemia Therapeutics Industry Opportunities and Challenges
  4. 4.4 Acute Myeloid Leukaemia Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Acute Myeloid Leukaemia Therapeutics Revenue (2021-2026)
  2. 5.2 Global Acute Myeloid Leukaemia Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Acute Myeloid Leukaemia Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Acute Myeloid Leukaemia Therapeutics Company, Product Type & Application
  5. 5.5 Global Acute Myeloid Leukaemia Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Acute Myeloid Leukaemia Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Acute Myeloid Leukaemia Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Acute Myeloid Leukaemia Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Pfizer Inc.
  2. 6.1.1 Pfizer Inc. Company Information
  3. 6.1.2 Pfizer Inc. Business Overview
  4. 6.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  6. 6.1.5 Pfizer Inc. Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Celgene Corporation
  14. 6.3.1 Celgene Corporation Company Information
  15. 6.3.2 Celgene Corporation Business Overview
  16. 6.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product Portfolio
  18. 6.3.5 Celgene Corporation Recent Developments
  19. 6.4 Astellas Pharma Inc.
  20. 6.4.1 Astellas Pharma Inc. Company Information
  21. 6.4.2 Astellas Pharma Inc. Business Overview
  22. 6.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  24. 6.4.5 Astellas Pharma Inc. Recent Developments
  25. 6.5 Daiichi Sankyo Company, Limited
  26. 6.5.1 Daiichi Sankyo Company, Limited Company Information
  27. 6.5.2 Daiichi Sankyo Company, Limited Business Overview
  28. 6.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  30. 6.5.5 Daiichi Sankyo Company, Limited Recent Developments
  31. 6.6 Jazz Pharmaceuticals
  32. 6.6.1 Jazz Pharmaceuticals Company Information
  33. 6.6.2 Jazz Pharmaceuticals Business Overview
  34. 6.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product Portfolio
  36. 6.6.5 Jazz Pharmaceuticals Recent Developments
  37. 6.7 Boehringer Ingelheim International GmbH
  38. 6.7.1 Boehringer Ingelheim International GmbH Company Information
  39. 6.7.2 Boehringer Ingelheim International GmbH Business Overview
  40. 6.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product Portfolio
  42. 6.7.5 Boehringer Ingelheim International GmbH Recent Developments
  43. 6.8 Johnson & Johnson
  44. 6.8.1 Johnson & Johnson Company Information
  45. 6.8.2 Johnson & Johnson Business Overview
  46. 6.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product Portfolio
  48. 6.8.5 Johnson & Johnson Recent Developments
  49. 6.9 Gilead Sciences, Inc.
  50. 6.9.1 Gilead Sciences, Inc. Company Information
  51. 6.9.2 Gilead Sciences, Inc. Business Overview
  52. 6.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  54. 6.9.5 Gilead Sciences, Inc. Recent Developments
  55. 6.10 Amgen Inc.
  56. 6.10.1 Amgen Inc. Company Information
  57. 6.10.2 Amgen Inc. Business Overview
  58. 6.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  60. 6.10.5 Amgen Inc. Recent Developments
  61. 6.11 Takeda Pharmaceutical Company Limited
  62. 6.11.1 Takeda Pharmaceutical Company Limited Company Information
  63. 6.11.2 Takeda Pharmaceutical Company Limited Business Overview
  64. 6.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product Portfolio
  66. 6.11.5 Takeda Pharmaceutical Company Limited Recent Developments
  67. 6.12 Sunesis Pharmaceuticals, Inc.
  68. 6.12.1 Sunesis Pharmaceuticals, Inc. Company Information
  69. 6.12.2 Sunesis Pharmaceuticals, Inc. Business Overview
  70. 6.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  72. 6.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments
  73. 6.13 Agios Pharmaceuticals, Inc.
  74. 6.13.1 Agios Pharmaceuticals, Inc. Company Information
  75. 6.13.2 Agios Pharmaceuticals, Inc. Business Overview
  76. 6.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product Portfolio
  78. 6.13.5 Agios Pharmaceuticals, Inc. Recent Developments
7 North America
  1. 7.1 North America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst